Hospital
The Valley Hospital INC.
The Valley Hospital INC. was paid $31.48M by Medicaid between Jan 2018 and Nov 2024, across 257 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoTHE VALLEY HOSPITAL INC.
RIDGEWOOD, NJ 07450
RIDGEWOOD, NJ 07450
33aNPI1013912633assigned 06/20/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$31.48M
24GClaims641,766
24DCodes billed257
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#46 of 93
Median peer was paid$30.60M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,527 | $3.36M | |
| 2019 | 56,983 | $3.79M | |
| 2020 | 48,815 | $2.53M | |
| 2021 | 90,278 | $4.70M | |
| 2022 | 136,671 | $6.11M | |
| 2023 | 147,142 | $6.23M | |
| 2024incomplete | 116,350 | $4.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 16,190 | 14,012 | $5.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 16,090 | 14,766 | $4.06M |
| G0378 | Hospital observation service, per hour | 11% | 4,165 | 3,191 | $3.50M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 8,186 | 7,019 | $3.41M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.2% | 6,615 | 4,576 | $997K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 3.1% | 3,493 | 2,987 | $979K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.0% | 575 | 475 | $930K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.7% | 8,315 | 5,790 | $852K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 3,556 | 3,142 | $796K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.2% | 6,774 | 6,125 | $689K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 3,992 | 3,755 | $686K |
| OP710 | 1.4% | 4,509 | 3,664 | $429K |
245 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,848 | $356K |
| OP272 | 1.0% | 10,001 | $319K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,851 | $314K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 15,870 | $290K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,559 | $289K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,128 | $287K |
| OP259 | <1% | 28,377 | $246K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 794 | $245K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,856 | $236K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,977 | $227K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,299 | $208K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,382 | $204K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,928 | $187K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,148 | $179K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,401 | $157K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,400 | $155K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,037 | $154K |
| 80053 | Comprehensive metabolic panel | <1% | 24,753 | $149K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,023 | $147K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,623 | $140K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 112 | $135K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,620 | $130K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,596 | $129K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,241 | $127K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 501 | $124K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,244 | $123K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,187 | $122K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,332 | $122K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,653 | $118K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,470 | $112K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,651 | $106K |
| A0425 | Ground mileage, per statute mile | <1% | 8,211 | $99K |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,592 | $90K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,096 | $88K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,779 | $86K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,402 | $84K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,428 | $78K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,247 | $73K |
| 93970 | <1% | 721 | $73K | |
| 76830 | Ultrasound, transvaginal | <1% | 827 | $67K |
| 76818 | <1% | 688 | $63K | |
| 0002A | <1% | 2,235 | $61K | |
| 0001A | <1% | 2,324 | $60K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,308 | $58K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,263 | $58K |
| 86901 | <1% | 3,123 | $53K | |
| 84484 | <1% | 8,566 | $46K | |
| OP762 | <1% | 313 | $45K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 992 | $45K |
| 96376 | <1% | 3,037 | $45K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,930 | $44K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 565 | $42K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,130 | $40K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 392 | $37K |
| J3490 | Unclassified drugs | <1% | 4,221 | $36K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,756 | $35K |
| 76801 | <1% | 387 | $33K | |
| 80306 | <1% | 2,075 | $33K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,644 | $33K |
| 83735 | <1% | 7,776 | $32K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 508 | $32K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 368 | $31K |
| 96367 | <1% | 1,543 | $30K | |
| 81001 | <1% | 14,799 | $28K | |
| 83880 | <1% | 3,338 | $28K | |
| 87486 | <1% | 800 | $27K | |
| 86900 | <1% | 3,109 | $27K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,232 | $27K |
| 86850 | <1% | 3,184 | $27K | |
| 80061 | Lipid panel | <1% | 5,449 | $26K |
| 97161 | <1% | 735 | $26K | |
| 82962 | <1% | 5,539 | $26K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,497 | $26K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $26K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 352 | $26K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 807 | $26K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,929 | $25K |
| 80076 | <1% | 5,939 | $25K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,464 | $25K |
| 87581 | <1% | 800 | $25K | |
| 84439 | <1% | 5,263 | $24K | |
| 85610 | <1% | 8,705 | $24K | |
| 85027 | <1% | 7,596 | $23K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 404 | $23K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 209 | $22K |
| 84100 | <1% | 5,552 | $22K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 72 | $22K |
| 73560 | <1% | 981 | $22K | |
| 76642 | <1% | 322 | $21K | |
| 84703 | <1% | 5,036 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,115 | $21K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,024 | $20K |
| 80320 | <1% | 1,164 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,785 | $20K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 949 | $19K |
| 83605 | <1% | 2,101 | $19K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,586 | $19K |
| 83690 | <1% | 6,038 | $18K | |
| 87040 | <1% | 2,173 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,112 | $16K |
| 92526 | <1% | 382 | $15K | |
| 90715 | <1% | 527 | $15K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 962 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,357 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 814 | $14K |
| 84702 | <1% | 2,033 | $13K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 379 | $13K |
| 90688 | <1% | 611 | $13K | |
| 71250 | <1% | 168 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,806 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,550 | $12K |
| 73610 | <1% | 503 | $11K | |
| 72131 | <1% | 209 | $11K | |
| 77066 | Tomosynthesis, mammo | <1% | 91 | $11K |
| 77080 | <1% | 129 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 795 | $10K |
| OP258 | <1% | 107 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,854 | $9K |
| 97162 | <1% | 280 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,004 | $9K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 101 | $8K |
| 73030 | <1% | 436 | $8K | |
| 97116 | <1% | 287 | $8K | |
| 0003A | <1% | 303 | $7K | |
| 80329 | <1% | 332 | $7K | |
| 81003 | <1% | 3,578 | $7K | |
| 73630 | <1% | 313 | $7K | |
| 85730 | <1% | 2,020 | $6K | |
| OP278 | <1% | 297 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 551 | $6K |
| 88342 | <1% | 887 | $6K | |
| 86140 | <1% | 2,778 | $6K | |
| 81025 | <1% | 2,747 | $6K | |
| 0031A | <1% | 213 | $5K | |
| 87077 | <1% | 1,890 | $5K | |
| 0011A | <1% | 164 | $5K | |
| 87186 | <1% | 1,730 | $5K | |
| 74018 | <1% | 290 | $4K | |
| 90697 | <1% | 39 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,452 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,545 | $4K |
| 85378 | <1% | 1,262 | $4K | |
| 87806 | <1% | 167 | $4K | |
| 73110 | <1% | 141 | $4K | |
| 84145 | <1% | 1,045 | $4K | |
| 0012A | <1% | 139 | $4K | |
| 82565 | <1% | 1,316 | $4K | |
| 86780 | <1% | 364 | $4K | |
| 82607 | <1% | 1,582 | $3K | |
| 82947 | <1% | 556 | $3K | |
| 85652 | <1% | 2,184 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,264 | $3K |
| 82728 | <1% | 1,080 | $3K | |
| 82248 | <1% | 783 | $3K | |
| 83550 | <1% | 1,188 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 306 | $2K |
| 90756 | <1% | 84 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $2K |
| 0071A | <1% | 76 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 83540 | <1% | 1,341 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 41 | $2K |
| 76536 | <1% | 30 | $2K | |
| 0072A | <1% | 60 | $2K | |
| 73502 | <1% | 134 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,357 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 167 | $2K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 50 | $2K |
| 96161 | <1% | 179 | $2K | |
| C1769 | Guide wire | <1% | 204 | $1K |
| 0013A | <1% | 76 | $1K | |
| 80164 | <1% | 674 | $1K | |
| 76641 | <1% | 14 | $1K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 637 | $1K |
| 92610 | <1% | 18 | $1K | |
| 87390 | <1% | 72 | $1K | |
| 86328 | <1% | 32 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 471 | $942.55 |
| 86702 | <1% | 73 | $930.18 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 74 | $889.41 |
| 73130 | <1% | 48 | $864.04 | |
| 94760 | <1% | 17 | $840.98 | |
| 86701 | <1% | 72 | $840.29 | |
| 72100 | <1% | 48 | $835.29 | |
| 82550 | <1% | 500 | $755.58 | |
| G0008 | Administration of influenza virus vaccine | <1% | 70 | $754.52 |
| 82746 | <1% | 584 | $705.90 | |
| 73140 | <1% | 27 | $670.45 | |
| 90670 | <1% | 14 | $655.78 | |
| 86618 | <1% | 60 | $571.81 | |
| 86665 | <1% | 40 | $566.25 | |
| 82247 | <1% | 121 | $554.10 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 158 | $423.09 |
| 84295 | <1% | 214 | $373.76 | |
| 87070 | <1% | 68 | $363.65 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 30 | $348.67 |
| 82330 | <1% | 63 | $326.31 | |
| 84480 | <1% | 122 | $301.80 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 40 | $301.22 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 260 | $288.36 |
| 82435 | <1% | 214 | $283.55 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $261.64 |
| 86664 | <1% | 40 | $242.98 | |
| 92551 | <1% | 43 | $237.43 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 66 | $231.10 |
| 82570 | <1% | 526 | $223.30 | |
| 87340 | <1% | 43 | $221.40 | |
| 84550 | <1% | 231 | $210.27 | |
| 99441 | <1% | 27 | $205.84 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 65 | $199.41 |
| 90380 | <1% | 13 | $165.65 | |
| 87205 | <1% | 176 | $162.62 | |
| 99173 | <1% | 56 | $153.95 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 227 | $146.98 |
| 73590 | <1% | 14 | $146.13 | |
| 0124A | <1% | 14 | $145.80 | |
| 96368 | <1% | 16 | $144.02 | |
| 82043 | <1% | 262 | $121.16 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 220 | $112.57 |
| 87071 | <1% | 70 | $100.74 | |
| 80178 | <1% | 63 | $98.95 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 305 | $92.78 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 46 | $90.05 |
| 86308 | <1% | 29 | $89.48 | |
| 90473 | <1% | 24 | $80.50 | |
| 84436 | <1% | 171 | $67.71 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $67.17 |
| 85014 | <1% | 68 | $48.96 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 16 | $36.74 |
| 82784 | <1% | 13 | $33.90 | |
| 83615 | <1% | 30 | $28.44 | |
| 88304 | <1% | 13 | $28.11 | |
| J2704 | Injection, propofol, 10 mg | <1% | 24 | $27.98 |
| 84132 | <1% | 38 | $25.50 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 16 | $22.17 |
| 85018 | <1% | 16 | $15.40 | |
| 84165 | <1% | 17 | $12.00 | |
| 99177 | <1% | 13 | $11.64 | |
| 36416 | <1% | 33 | $9.00 | |
| 82310 | <1% | 15 | $8.20 | |
| 84540 | <1% | 12 | $7.00 | |
| 90698 | <1% | 12 | $4.00 | |
| 90461 | 0% | 119 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 13 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEYERS, AUDREY (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Valley Physician Services, NY, PC | Ridgewood, NJ | $403.27 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.